Home › NDC Lookup › RxCUI directory › RxCUI 2049119

Encorafenib 75 MG Oral Capsule — RxCUI 2049119

RxNorm drug concept · Semantic clinical drug
RxCUI 2049119 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2049119
Official nameEncorafenib 75 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped1
Package NDCs mapped4
Reported Medicaid activity (SDUD)949 prescriptions · 14 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Encorafenib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats melanoma, colorectal cancer and non-small cell lung cancer that carry a BRAF V600E mutation (V600K too in melanoma). A test confirms the mutation first. You take it toget...
  • Take the capsules by mouth once a day, with or without food. If you miss a dose, skip it if your next dose is within 12 hours. If you vomit after taking it, don't take extra. Just...
  • Common ones are tiredness, nausea, vomiting, belly pain, diarrhea or constipation, joint pain and rash. Tell your care team if these get hard to handle, since the dose can be adjus...
  • Call about any bleeding, vision changes, new shortness of breath or swelling, fainting or a racing heartbeat, or new skin growths. Regular skin, eye, heart and blood checks are par...
📖 Read our full Encorafenib guide →

🕸️ Concept Web — How Encorafenib 75 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Encorafenib 75 MG Oral Capsule RxCUI 2049119

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Encorafenib 2049106
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Braftovi 2049112
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Encorafenib Oral Capsule 2049110
    • Encorafenib Oral Product 2049108
    • Encorafenib Pill 2049109
    • Encorafenib Oral Capsule [Braftovi] 2049114
    • Braftovi Oral Product 2049115
    • Braftovi Pill 2049116
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Encorafenib 75 MG SCDC · 2049118
  • Encorafenib Oral Capsule SCDF · 2049110
  • Encorafenib Oral Product SCDG · 2049108
  • Encorafenib Pill SCDG · 2049109

Brand-Name Concepts

  • Encorafenib 75 MG Oral Capsule [Braftovi] SBD · 2049121
  • Encorafenib 75 MG [Braftovi] SBDC · 2049120
  • Encorafenib Oral Capsule [Braftovi] SBDF · 2049114
  • Braftovi Oral Product SBDG · 2049115
  • Braftovi Pill SBDG · 2049116
  • Braftovi BN · 2049112

📦 FDA Products & Package NDCs

1 product · 4 package NDCs
4 package NDCs map to RxCUI 2049119 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
70255-0025-01 2 BOTTLE in 1 CARTON (70255-025-01) / 90 CAPSULE in 1 BOTTL... BRAFTOVI Array BioPharma Inc. 2018-06-27
70255-0025-03 2 BOTTLE in 1 CARTON (70255-025-03) / 60 CAPSULE in 1 BOTTL... BRAFTOVI Array BioPharma Inc. 2018-06-27
70255-0025-05 90 CAPSULE in 1 BOTTLE (70255-025-05) BRAFTOVI Array BioPharma Inc. 2020-08-03
70255-0025-06 60 CAPSULE in 1 BOTTLE (70255-025-06) BRAFTOVI Array BioPharma Inc. 2020-08-03
Observed labelers: Array BioPharma Inc. (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.